NOVO.B.DK

429.8

-5.94%↓

COLO.B.DK

690.8

-0.78%↓

ZEAL.DK

422.2

-8.69%↓

HLUNB.DK

30.24

-5.68%↓

AMBUB.DK

107.85

-1.51%↓

NOVO.B.DK

429.8

-5.94%↓

COLO.B.DK

690.8

-0.78%↓

ZEAL.DK

422.2

-8.69%↓

HLUNB.DK

30.24

-5.68%↓

AMBUB.DK

107.85

-1.51%↓

NOVO.B.DK

429.8

-5.94%↓

COLO.B.DK

690.8

-0.78%↓

ZEAL.DK

422.2

-8.69%↓

HLUNB.DK

30.24

-5.68%↓

AMBUB.DK

107.85

-1.51%↓

NOVO.B.DK

429.8

-5.94%↓

COLO.B.DK

690.8

-0.78%↓

ZEAL.DK

422.2

-8.69%↓

HLUNB.DK

30.24

-5.68%↓

AMBUB.DK

107.85

-1.51%↓

NOVO.B.DK

429.8

-5.94%↓

COLO.B.DK

690.8

-0.78%↓

ZEAL.DK

422.2

-8.69%↓

HLUNB.DK

30.24

-5.68%↓

AMBUB.DK

107.85

-1.51%↓

Search

Genmab A-S

Closed

1,250.5 -2.61

Overview

Share price change

24h

Current

Min

1247.5

Max

1268

Key metrics

By Trading Economics

Income

2.1B

3.8B

Sales

901M

6.4B

P/E

Sector Avg

11.038

63.778

EPS

60.121

Profit margin

59.696

Employees

2,682

EBITDA

-297M

1.8B

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

-1.49% downside

Dividends

By Dow Jones

Next Earnings

1 maj 2025

Market Stats

By TradingEconomics

Market Cap

-5.2B

85B

Previous open

1253.11

Previous close

1250.5

Genmab A-S Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 mar 2025, 15:16 UTC

Major Market Movers

Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option

10 gru 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Peer Comparison

Price change

Genmab A-S Forecast

Price Target

By TipRanks

-1.49% downside

12 Months Forecast

Average 2,493.35 DKK  -1.49%

High 3,320 DKK

Low 308.417 DKK

Based on 7 Wall Street analysts offering 12 month price targets forGenmab A-S - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

7 ratings

3

Buy

2

Hold

2

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.